Translational Research &Pharmacology Core Program Director/Principal Investigator: Gerson, Stanton L. PROJECT SUMMARY (See instructions): The primary role of the Translation Research &Pharmacology Core is to facilitate the implementation of scientifically rigorous correlative study components for Case CCC clinical trials. The Core has four components - a central office and cellular and molecular biology lab;a clinical processing lab;a clinical pharmacology lab;and a cancer pharmacology (mass spectrometry) lab. Core staff is composed of an experienced team dedicated to facilitating all aspects of the correlative study components of Case CCC clinical trials, guaranteeing consistent quality control. The TRC also includes an effort initially supported with UOl funds to perform in vitro testing of new drugs and combination therapies. The central, clinical processing and pharmacology labs are administered by the Case CCC, while the clinical pharmacology lab is managed through Cleveland Clinic, but is part of this Core operation. The service is to support correlative studies within Case CCC clinical trials. Support from the CCSG stabilizes the Core financially and provides clinical investigators formal ability to obtain clinical correlates. Formal access to Core services is extended to Case CCC members across the consortium sites. Services provided by the Core include: 1) consultation or full service writing of methods sections and budgets for CTEP letters of intent, protocols, and grants;2) sample informatics and correlate data;3) data analysis;4) sample handling (receiving, storage, distribution);5) sample processing (dispensing whole blood aliquots, routine blood processing, DNA, RNA and protein extraction, flow or laser scanning cytometry staining);6) lab analysis (western blots, ELISAs, MSD multiplex analysis, PARP activity and Poly(ADP)-ribose assay, comet assays);7) single or multiple agent cytotoxicity multiple agent analysis), 8) pharmacokinetic assay development, and 9) pharmacokinetic assay performance. The Core handles specimens from ~100 trials per year, members from all of the Case CCC Scientific Research Programs utilize the Core, and the user base is >95% Case CCC membership. The Core played a key role in numerous projects including: the first-in-human trial of the base excision inhibitor methoxyamine used in combination with temozolomide (Cancer Pharmacology Lab) and the design and operation ofthe Gl SPORE Biospecimen Core.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Zhao, S; Sedwick, D; Wang, Z (2015) Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene 34:3885-94|
|Dermawan, Josephine Kam Tai; Gurova, Katerina; Pink, John et al. (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-?B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13:2203-14|
|Brubaker, Douglas; Difeo, Analisa; Chen, Yanwen et al. (2014) Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pac Symp Biocomput :125-35|
|Yori, Jennifer L; Lozada, Kristen L; Seachrist, Darcie D et al. (2014) Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res 74:4762-71|
|Dabir, Snehal; Kluge, Amy; McColl, Karen et al. (2014) PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 134:1045-54|
|Zapanta Rinonos, Serendipity; Rai, Urvashi; Vereb, Sydney et al. (2014) Sequential logic of polarity determination during the haploid-to-diploid transition in Saccharomyces cerevisiae. Eukaryot Cell 13:1393-402|
|Sizemore, Gina M; Sizemore, Steven T; Seachrist, Darcie D et al. (2014) GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem 289:24102-13|
|Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao et al. (2014) Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J 28:2260-71|
|Dotan, Efrat; Devarajan, Karthik; D'Silva, A James et al. (2014) Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer 13:192-8|
|Arachiche, Amal; de la Fuente, María; Nieman, Marvin T (2014) Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets. PLoS One 9:e97724|
Showing the most recent 10 out of 975 publications